Next Article in Journal
Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation
Previous Article in Journal
QSAR and Molecular Docking Studies of Oxadiazole-Ligated Pyrrole Derivatives as Enoyl-ACP (CoA) Reductase Inhibitors
 
 
Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound

1
Lotus Labs Pvt. Ltd, Bangalore, India
2
Birla Institute of Technology, Ranchi, India
3
Lotus Clinical Research Academy, Bangalore, India
4
Institute of Chemical Technology, Mumbai, India
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2014, 82(1), 87-98; https://doi.org/10.3797/scipharm.1308-15
Submission received: 31 August 2013 / Accepted: 21 October 2013 / Published: 21 October 2013

Abstract

Cyclohex-3-enyl(5-phenyl-4H-1,2,4-triazol-3-yl)methanol (MSDRT 12) is a novel triazole-based antitubercular compound with two chiral centers. To evaluate the enantiospecific antitubercular activity, the four stereoisomers were isolated using preparative chiral chromatography and the individual stereoisomers were evaluated using the resazurin microtiter assay method (REMA) and a microbroth dilution technique against the Mycobacterium tuberculosis H37Rv strain. Isomer III of MSDRT 12 was found to be the most potent with a minimum inhibitory concentration (MIC) of 0.78 μg/mL, Isomer II had a MIC of 12.5 μg/mL, and isomers I and IV showed no activity. The diastereomeric mixture of MSDRT 12 showed a MIC of 3.125 μg/mL and isoniazid, used as the standard drug, showed a MIC of 0.4 μg/mL. This confirms the necessity of screening individual enantiomers for their pharmacological activity early in the discovery phase to identify the most potent isomer for further development efforts.
Keywords: Chiral Separation; Preparative Chiral Chromatography; Triazoles; Antitubercular Compounds; REMA testing Chiral Separation; Preparative Chiral Chromatography; Triazoles; Antitubercular Compounds; REMA testing

Share and Cite

MDPI and ACS Style

SHEKAR, R.; SINHA, B.N.; MUKHOPADHYA, A.; DEGANI, M.S. Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound. Sci. Pharm. 2014, 82, 87-98. https://doi.org/10.3797/scipharm.1308-15

AMA Style

SHEKAR R, SINHA BN, MUKHOPADHYA A, DEGANI MS. Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound. Scientia Pharmaceutica. 2014; 82(1):87-98. https://doi.org/10.3797/scipharm.1308-15

Chicago/Turabian Style

SHEKAR, Radha, Barij Nayan SINHA, Arindam MUKHOPADHYA, and Mariam S. DEGANI. 2014. "Isolation and Evaluation of the Enantiospecific Antitubercular Activity of a Novel Triazole Compound" Scientia Pharmaceutica 82, no. 1: 87-98. https://doi.org/10.3797/scipharm.1308-15

Article Metrics

Back to TopTop